Kiyono H - Search Results

1

Development of a nanogel-based nasal vaccine as a novel antigen delivery system.

Nakahashi-Ouchida R, Yuki Y, Kiyono H. Nakahashi-Ouchida R, et al. Among authors: kiyono h. Expert Rev Vaccines. 2017 Dec;16(12):1231-1240. doi: 10.1080/14760584.2017.1395702. Epub 2017 Oct 27. Expert Rev Vaccines. 2017. PMID: 29053938 Review.

2

[Mucosal immune system and mucosal vaccine].

Yanagita M, Hiroi T, Kiyono H. Yanagita M, et al. Among authors: kiyono h. Nihon Rinsho. 1997 Feb;55(2):492-501. Nihon Rinsho. 1997. PMID: 9046845 Review. Japanese.

3

Human milk proteins including secretory IgA fail to elicit tolerance after feeding.

Yuki Y, Fujihashi K, Yamamoto M, McGhee JR, Kiyono H. Yuki Y, et al. Among authors: kiyono h. Int Immunol. 1998 Apr;10(4):537-45. doi: 10.1093/intimm/10.4.537. Int Immunol. 1998. PMID: 9620610

4

Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies.

Byun Y, Ohmura M, Fujihashi K, Yamamoto S, McGhee JR, Udaka S, Kiyono H, Takeda Y, Kohsaka T, Yuki Y. Byun Y, et al. Among authors: kiyono h. Vaccine. 2001 Feb 28;19(15-16):2061-70. doi: 10.1016/s0264-410x(00)00411-4. Vaccine. 2001. PMID: 11228378

5

Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis.

Yuki Y, Byun Y, Fujita M, Izutani W, Suzuki T, Udaka S, Fujihashi K, McGhee JR, Kiyono H. Yuki Y, et al. Among authors: kiyono h. Biotechnol Bioeng. 2001 Jul 5;74(1):62-9. doi: 10.1002/bit.1095. Biotechnol Bioeng. 2001. PMID: 11353411

6

Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE).

Yura M, Takahashi I, Serada M, Koshio T, Nakagami K, Yuki Y, Kiyono H. Yura M, et al. Among authors: kiyono h. J Autoimmun. 2001 Aug;17(1):17-25. doi: 10.1006/jaut.2001.0520. J Autoimmun. 2001. PMID: 11488634

7

Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE).

Yura M, Takahashi I, Terawaki S, Hiroi T, Kweon MN, Yuki Y, Kiyono H. Yura M, et al. Among authors: kiyono h. Vaccine. 2001 Oct 12;20(1-2):134-9. doi: 10.1016/s0264-410x(01)00278-x. Vaccine. 2001. PMID: 11567757

8

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR. Boyaka PN, et al. Among authors: kiyono h. J Immunol. 2003 Jan 1;170(1):454-62. doi: 10.4049/jimmunol.170.1.454. J Immunol. 2003. PMID: 12496431

9

[M cells: development and function].

Yuki Y, Kiyono H. Yuki Y, et al. Among authors: kiyono h. Tanpakushitsu Kakusan Koso. 2002 Dec;47(16 Suppl):2325-30. Tanpakushitsu Kakusan Koso. 2002. PMID: 12518456 Review. Japanese. No abstract available.

10

New generation of mucosal adjuvants for the induction of protective immunity.

Yuki Y, Kiyono H. Yuki Y, et al. Among authors: kiyono h. Rev Med Virol. 2003 Sep-Oct;13(5):293-310. doi: 10.1002/rmv.398. Rev Med Virol. 2003. PMID: 12931340 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

622 results

Search Page

Filters